Every Form 4 that Eton Pharmaceutcials, Inc. (ETON) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ETON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ETON filings page.
Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier reported multiple transactions on 2026-08-28. He exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and 12,500 shares at $7.31 per share, receiving common stock.
On the same date, he sold an aggregate of 50,000 common shares in open-market transactions: 36,387 shares at a weighted average price of $58.64 (range $58.50–$58.97), 13,485 shares at $60.21 (range $60.00–$61.00), and 128 shares at $61.77 (range $61.10–$61.98).
Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and concurrently sold 50,000 shares of common stock on 2026-08-28 in multiple open-market transactions at weighted-average prices between about $58.50 and $61.98 per share. Following the option exercise, the reported option position was reduced to zero.
Eton Pharmaceuticals, Inc. (ETON) reported insider equity activity by Chief Business Officer David Krempa. On 2026-08-24 he exercised an Employee Stock Option to acquire 25,000 shares of common stock at an exercise price of $7.31 per share, reducing that option position to 70,000 options remaining. The resulting 25,000 common shares were then sold in market transactions at a weighted average price of $65.07 per share, with individual sale prices ranging from $64.88 to $65.57. The option originally granted on 2019-02-20 vested in 48 equal monthly installments and expires on 2029-02-19. The filing indicates these transactions were not made pursuant to a Rule 10b5-1 trading plan.
Eton Pharmaceuticals, Inc. (ETON) reported that President & CEO Sean Brynjelsen sold a total of 100,000 shares of common stock in four open-market transactions on August 19–20, 2026. The sales used weighted average prices of $62.65, $62.12, $61.11, and $60.17 per share, each executed in multiple trades within stated price ranges.
CASAMENTO CHARLES J reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Charles J. Casamento received a grant of 10,000 performance-vested restricted stock units, each representing one share of common stock. The award vests in full only if the share price reaches $72.36 or higher for one trading day before July 31, 2029, otherwise it is forfeited.
Eton Pharmaceuticals, Inc. reported that Chief Financial Officer Judith M. Matthews received a grant of 32,246 performance-vested restricted stock units under the company's 2018 equity incentive plan. Each unit represents the right to acquire one share of common stock.
The award vests in full only if the closing price of Eton's common stock equals or exceeds $72.36 per share for one trading day at any time before July 31, 2029; if this market condition is not satisfied, the entire award is forfeited without consideration. The filing characterizes the transaction as a grant or award acquisition rather than an open-market purchase.
Erdogan-Trinkaus Ipek reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals granted Chief Commercial Officer Ipek Erdogan-Trinkaus 80,000 performance-vested restricted stock units on July 31, 2026 under its 2018 equity incentive plan. Each unit entitles the holder to one common share if the stock’s closing price reaches $72.36 or higher for one trading day within three years; otherwise the entire award, the only 80,000 shares issuable, is forfeited on July 31, 2029.
BRYNJELSEN SEAN reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals, Inc. granted President & CEO Sean Brynjelsen 128,985 performance-vested restricted stock units under its 2018 equity incentive plan on July 31, 2026.
Each unit represents one common share and vests only if the stock’s closing price reaches at least $72.36 for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without payment on July 31, 2029.
Eton Pharmaceuticals, Inc. reported that Chief Business Officer David Krempa received a grant of 128,985 performance-vested restricted stock units on July 31, 2026 under the 2018 equity incentive plan. Each unit may convert into one share of common stock if the closing price reaches $72.36 per share for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without consideration on July 31, 2029. The 128,985 units represent the maximum and only number of shares issuable under this award.
MAIER PAUL V reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Paul V Maier received a grant of 10,000 performance-vested restricted stock units on July 31, 2026 under the company’s 2018 equity incentive plan. Each unit equals one share and vests in full if the stock’s closing price reaches $72.36 for one trading day before July 31, 2029; otherwise the award is forfeited. After the grant, he holds 10,000 units, the maximum and only number of shares issuable under this award.
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Norbert G. Riedel received a grant of 10,000 performance-vested restricted stock units (RSUs) on July 31, 2026 under the 2018 equity incentive plan. Each RSU represents one common share and vests in full if the stock’s closing price reaches $72.36 or higher for one trading day before July 31, 2029; otherwise the entire award is forfeited. Following this grant, Riedel holds 10,000 such units.
Adams Jennifer McKie reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Jennifer McKie Adams received a grant of 10,000 performance‑vested restricted stock units under the 2018 equity incentive plan. Each unit represents one share, vesting only if the stock closes at $72.36 or higher for one trading day before July 31, 2029; otherwise the award is forfeited.
Eton Pharmaceuticals, Inc. ten percent owner Opaleye Management Inc., through a separately managed account and Opaleye, L.P., reported selling a total of 28,315 common shares on July 14, 2026 at a weighted average price of $37.5431 per share. After these indirect sales, the accounts held 40,000 and 2,665,000 shares, respectively, with Opaleye Management disclaiming beneficial ownership except for its pecuniary interest. The amendment states Opaleye Management is no longer subject to Section 16 reporting.
Opaleye Management Inc., a more-than-10% holder of Eton Pharmaceuticals, reported open-market sales totaling 28,315 shares of common stock on July 14, 2026 at a weighted average price of $37.5431 per share. The sales consisted of 13,315 shares held in a separately managed account and 15,000 shares held by Opaleye, L.P. Following these transactions, the managed account held 40,000 shares and Opaleye, L.P. held 2,665,000 shares, all reported as indirect holdings. Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported only equity acquisitions. He exercised employee stock options covering 200000.0000 shares of common stock at an exercise price of 1.3700 on July 14, 2026, and converted 27500.0000 shares from restricted stock units on July 12, 2026. After these derivative exercises, he directly holds 1061194.0000 common shares, with no sales, gifts, or tax-withholding dispositions reported.
Eton Pharmaceuticals, Inc. Chief Business Officer David Krempa exercised 10,000 Restricted Stock Units, converting them into an equal number of shares of common stock. These RSUs were part of a 40,000-unit grant awarded on July 12, 2022 that vests in four equal annual installments beginning July 12, 2023. Following this vesting-related exercise, Krempa holds 37,025 common shares directly.
Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., reported open-market sales totaling 126,685 shares of common stock from July 2 to July 7, 2026. The trades were executed at weighted average prices around $37–$38 per share.
Shares were sold through Opaleye, L.P. and a separately managed account for which Opaleye Management serves as investment manager or portfolio manager. After these transactions, Opaleye, L.P. held 2,680,000 shares, and the managed account held 53,315 shares. Opaleye Management states it may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Krempa David reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals Chief Business Officer David Krempa received a grant of 10,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in four equal annual installments starting on June 26, 2027, as long as he remains employed on each vesting date.
Following this award, Krempa directly holds a reported total of 96,829 derivative-based shares tied to Eton common stock. This filing reflects a compensation-related equity grant rather than an open-market purchase or sale.
Eton Pharmaceuticals director Jennifer McKie Adams reported an option exercise paired with an open-market sale of common stock. She exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share, then sold 50,000 shares in open-market transactions at a weighted average price of $32.4759 per share.
The sale was executed in multiple trades at prices ranging from $32.10 to $32.71, and the option grant, which vested quarterly, was fully vested by February 7, 2023. Following these transactions, Adams reported no remaining holdings of common stock or employee stock options.
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported open-market sales of a total of 120,000 shares of common stock on May 28, 2026. The transactions were executed at weighted-average prices, with individual trade prices ranging from $31.59 to $32.55 per share.
Following these sales, Brynjelsen directly held about 833,694 shares of Eton common stock. The filing notes that full details of the number of shares sold at each separate price are available upon request from the company, the SEC staff, or any security holder.
Eton Pharmaceuticals Chief Business Officer David Krempa exercised stock options and sold shares in several open-market trades. On May 22–27, 2026, he exercised options to acquire 87,794 shares of common stock at exercise prices of $1.37–$3.58 per share and sold 100,000 shares in open-market transactions at weighted average prices in the low-to-mid $30s, as detailed in the filing.
Following these transactions, he holds 25,249 shares of Eton common stock directly and retains 118,406 employee stock options, according to the reported post-transaction balances.
Eton Pharmaceuticals director Norbert G. Riedel reported option exercises that increased his common stock holdings. On April 21, 2026, he exercised employee stock options to acquire 19,655 shares of common stock at $8.61 per share and 12,500 shares at $7.31 per share, for a total of 32,155 shares. After these transactions, he directly owns 67,155 common shares and also has 157,145 common shares held indirectly through the “Norbert G. Riedel 2002 Trust, Loan Thi Tran 2002 Trust” family trust, where he serves as trustee.
Eton Pharmaceuticals director Norbert G. Riedel reported exercising stock options and acquiring additional common shares. On 02/03/2026, he exercised an employee stock option for 30,000 shares of common stock at $4.42 per share.
Following this transaction, he directly held 35,000 shares of Eton Pharmaceuticals common stock. He also had indirect beneficial ownership of 157,145 shares held in the “Norbert G. Riedel 2002 Trust, Loan Thi Tran 2002 Trust” family trust, where he serves as a trustee.
Eton Pharmaceuticals director Norbert G. Riedel reported new equity compensation grants. On January 12, 2026, he was granted options to purchase 12,196 shares of common stock at an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are scheduled to be fully vested and exercisable by January 12, 2027.
On the same date, he also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in four equal annual installments beginning January 12, 2027, contingent on his continued service with the company on each vesting date. Following these grants, he beneficially owns 294,253 derivative securities directly.
Eton Pharmaceuticals director Adams Jennifer McKie reported new equity awards. On January 12, 2026, she received an employee stock option grant for 12,196 shares with an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are expected to be fully vested and exercisable by January 12, 2027.
She also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in one annual installment beginning January 12, 2027, contingent on her continued service with the company on the vesting date(s). Following these grants, she beneficially owns 170,329 derivative securities related to stock options and 178,086 derivative securities related to RSUs, all held directly.
Eton Pharmaceuticals director Charles J. Casamento reported new equity awards. On January 12, 2026, he received an employee stock option covering 12,196 shares of Eton common stock with an exercise price of $15.47 per share. According to the filing, these option shares vest quarterly over 12 months from the grant date and become fully vested and exercisable on January 12, 2027.
On the same date, he was also granted 7,757 restricted stock units. Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in a single annual installment beginning January 12, 2027, conditioned on his continued employment with the company on the vesting date. Following these grants, he beneficially owned 295,171 derivative securities related to options and 302,928 derivative securities related to restricted stock units.
Eton Pharmaceuticals director Paul V. Maier reported new equity awards. On January 12, 2026, he received an employee stock option for 12,196 shares of common stock at a $15.47 exercise price. These options vest quarterly over 12 months from the grant date and are fully exercisable on January 12, 2027.
He also received 7,757 restricted stock units, each representing a contingent right to one share of Eton common stock. These RSUs vest in one annual installment beginning January 12, 2027, contingent on his continued employment with the company. After these derivative awards, the filing shows 286,496 derivative securities following the option grant and 294,253 following the RSU grant, all held directly.
Eton Pharmaceuticals Chief Commercial Officer Erdogan-Trinkaus Ipek reported new equity awards. On January 12, 2026, the executive received an employee stock option for 40,655 shares of common stock at an exercise price of $15.47 per share. These options vest in 48 equal monthly installments from the grant date and become fully vested and exercisable on January 12, 2030.
The filing also shows a grant of 25,856 restricted stock units (RSUs), each representing one share of ETON common stock. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on continued employment on each vesting date. After these grants, the reporting person beneficially owns 123,878 derivative securities tied to options and 149,734 derivative securities tied to RSUs.
Eton Pharmaceuticals President & CEO Sean Brynjelsen, also a director and 10% owner, reported multiple equity transactions. On January 1, 2026, 5,015 shares of common stock were disposed of at a weighted average price of $15.39, with shares withheld by the company to satisfy taxes upon vesting of restricted stock units, leaving him with 2,889,266 common shares held directly.
On January 12, 2026, he was granted an employee stock option for 158,046 shares at an exercise price of $15.47, vesting in 48 equal monthly installments until fully vested and exercisable on January 12, 2030, and expiring January 11, 2036. He also received 100,517 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning January 12, 2027, contingent on continued employment.
Eton Pharmaceuticals chief business officer David Krempa reported new equity awards and related tax withholding transactions. On January 12, 2026, he was granted 40,655 employee stock options with an exercise price of $15.47 per share, vesting in 48 equal monthly installments until fully vested and exercisable on January 12, 2030, and expiring on January 11, 2036. He also received 25,856 restricted stock units, each representing a right to one share of Eton common stock, vesting in four equal annual installments beginning January 12, 2027, contingent on continued employment. On January 14, 2026, 1,942 shares of common stock were withheld at $15.62 per share to cover taxes on RSU vesting, leaving 630,238 common shares beneficially owned directly, 670,893 derivative securities from options, and 696,749 derivative securities including RSUs.
Eton Pharmaceuticals Chief Financial Officer James R. Gruber reported routine equity compensation activity and related tax withholding. On January 12, 2026, he received an option grant for 40,655 shares of common stock at an exercise price of $15.47 per share, scheduled to vest in 48 equal monthly installments until January 12, 2030. He also received 25,856 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning January 12, 2027, contingent on continued employment.
On January 14, 2026, 2,293 shares of common stock were withheld and sold at a weighted average price of $15.47 to satisfy withholding taxes upon vesting of restricted stock units. After this transaction, Gruber beneficially owned 213,420 shares of common stock directly.
Eton Pharmaceuticals’ Chief Commercial Officer James R. Gruber reported a small equity-compensation-related stock disposition.
On December 12, 2025, 85 shares of Eton common stock were withheld by the issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units, with shares sold in multiple trades at prices ranging from $16.90 to $16.91 and a weighted average sales price reported. After this transaction, Gruber beneficially owned 2,403 Eton Pharmaceuticals common shares directly.
Eton Pharmaceuticals’ Chief Business Officer reported routine equity compensation and related share withholding. On 12/11/2025, the officer was awarded 5,300 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock, and the RSUs vest immediately as of the award date.
On 12/12/2025, 6,264 shares of common stock were disposed of under transaction code F, with a reported price of $17, in connection with shares withheld by the issuer to satisfy withholding taxes upon RSU vesting. These shares were sold in multiple trades at prices ranging from $16.83 to $17.11, and the reported price reflects the weighted average sales price. After these transactions, the officer directly beneficially owns 632,180 shares of common stock and 638,468 RSUs.
Eton Pharmaceuticals Chief Financial Officer James R. Gruber reported changes in his equity holdings. On 12/11/2025, he received 5,502 restricted stock units, each representing one share of common stock, which vested immediately and increased his total restricted stock unit holdings to 210,255. On 12/12/2025, 4,542 common shares were disposed of in a transaction coded “F” at a weighted average price of $16.99 per share, with shares withheld to satisfy tax obligations and sold in multiple trades between $16.94 and $17.07. After these transactions, he directly owned 215,713 shares of Eton common stock.
Eton Pharmaceuticals, Inc. reported an insider stock transaction by a person who serves as its President & CEO, director, and 10% owner. On 12/12/2025, 6,732 shares of common stock were disposed of in a transaction coded "F," which reflects shares withheld by the company to cover withholding taxes upon the vesting of restricted stock units. The shares were sold at a weighted average price of $16.83.
Following this tax-related transaction, the reporting person directly beneficially owns 2,894,281 shares of Eton Pharmaceuticals common stock.